MDM2 and myeloproliferative neoplasm: An additional in vitro study using cultured TP53 mutated and non-mutated CD34+ progenitors derived from patients with MPN clearly established that the exposure to an MDM2 inhibitor was directly responsible for the clonal selection of TP53-mutated cells [40].